SwePub
Sök i LIBRIS databas

  Utökad sökning

id:"swepub:oai:DiVA.org:uu-393537"
 

Sökning: id:"swepub:oai:DiVA.org:uu-393537" > A Fully Automated M...

A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients

Klaasen, Rolf Anton (författare)
Oslo Univ Hosp, Radiumhosp, Dept Med Biochem, Oslo, Norway;Oslo Univ Hosp, Rikshosp, Dept Pharmacol, Oslo, Norway
Egeland, Erlend Johannessen (författare)
Univ Oslo, Sch Pharm, Dept Pharmaceut Biosci, Postbox 1068 Blindern, N-0316 Oslo, Norway
Chan, Joe (författare)
Akershus Univ Hosp, Dept Renal Med, Lorenskog, Norway
visa fler...
Midtvedt, Karsten (författare)
Oslo Univ Hosp, Rikshosp, Dept Transplantat Med, Oslo, Norway
Svensson, My (författare)
Akershus Univ Hosp, Dept Renal Med, Lorenskog, Norway
Boltad, Nils (författare)
Oslo Univ Hosp, Radiumhosp, Dept Med Biochem, Oslo, Norway
Fellström, Bengt, 1947- (författare)
Uppsala universitet,Institutionen för medicinska vetenskaper,Uppsala Univ, Dept Med Sci, Uppsala, Sweden
Holdaas, Hallvard (författare)
Oslo Univ Hosp, Rikshosp, Dept Transplantat Med, Oslo, Norway
Asberg, Anders (författare)
Univ Oslo, Sch Pharm, Dept Pharmaceut Biosci, Postbox 1068 Blindern, N-0316 Oslo, Norway
Bergan, Stein (författare)
Oslo Univ Hosp, Rikshosp, Dept Pharmacol, Oslo, Norway
Teethe, Nils Tore (författare)
Oslo Univ Hosp, Rikshosp, Dept Pharmacol, Oslo, Norway
Warren, David John (författare)
Oslo Univ Hosp, Radiumhosp, Dept Med Biochem, Oslo, Norway
visa färre...
 (creator_code:org_t)
LIPPINCOTT WILLIAMS & WILKINS, 2019
2019
Engelska.
Ingår i: Therapeutic Drug Monitoring. - : LIPPINCOTT WILLIAMS & WILKINS. - 0163-4356 .- 1536-3694. ; 41:1, s. 11-18
  • Tidskriftsartikel (refereegranskat)
Abstract Ämnesord
Stäng  
  • Background: Belatacept (Nulojix; Bristol-Myers Squibb, New York, NY) is a biological immunosuppressive drug used for the prophylaxis of acute rejection after renal transplantation. Few studies have described belatacept pharmacokinetics, and the effect of therapeutic drug monitoring has not been investigated. We have developed a drug-capture assay (using drug target) to measure belatacept in serum and applied this assay in a pharmacokinetic study in renal transplant recipients. Methods: CD80 was used to trap belatacept onto streptavidin-coated wells. Captured drug was quantified using Eu3+-labeled protein A and time-resolved fluorescence. The assay was applied in a pilot pharmacokinetic study in renal transplanted patients receiving belatacept infusions. Belatacept serum concentrations were determined at several time points between belatacept infusions. A simple population pharmacokinetic model was developed to visualize measured and predicted belatacept serum concentrations. Results: The assay range was 0.9-30 mg/L with accuracy within 91%-99% and coefficients of variation ranging from 1.2% to 3.6%. Predilution extended the measurement range to 130 mg/L with an accuracy of 90% and coefficients of variation of 3.8%. Samples were stable during storage at 48 degrees C for 15 days and during 2 freeze-thaw cycles. Belatacept concentrations were determined in a total of 203 serum samples collected during 26 infusion intervals from 5 renal transplant recipients. The population pharmacokinetic model visualized both measured and predicted concentrations. Conclusions: We have developed an automated, accurate, and precise assay for the determination of belatacept serum concentrations. The assay was successfully applied in a pharmacokinetic study in renal transplant recipients receiving belatacept infusions.

Ämnesord

MEDICIN OCH HÄLSOVETENSKAP  -- Medicinska och farmaceutiska grundvetenskaper -- Farmaceutiska vetenskaper (hsv//swe)
MEDICAL AND HEALTH SCIENCES  -- Basic Medicine -- Pharmaceutical Sciences (hsv//eng)

Nyckelord

Belatacept
TDM
drug-capture assay
renal transplantation
pharmacokinetics

Publikations- och innehållstyp

ref (ämneskategori)
art (ämneskategori)

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy